These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 18540943)
1. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Gabrilove J; Paquette R; Lyons RM; Mushtaq C; Sekeres MA; Tomita D; Dreiling L Br J Haematol; 2008 Jul; 142(3):379-93. PubMed ID: 18540943 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468 [TBL] [Abstract][Full Text] [Related]
3. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Della Porta MG; Garcia-Manero G; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcárcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Pilot R; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Prebet T; Lai Y; Degulys A; Paolini S; Cluzeau T; Fenaux P; Platzbecker U Lancet Haematol; 2024 Sep; 11(9):e646-e658. PubMed ID: 39038479 [TBL] [Abstract][Full Text] [Related]
4. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887 [TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892 [TBL] [Abstract][Full Text] [Related]
6. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials. Krause MW; Raja R; Agarwal A; Silver MR; Scarlata D; Sciarra A; Kewalramani R Drugs Aging; 2009; 26(8):665-75. PubMed ID: 19685932 [TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340 [TBL] [Abstract][Full Text] [Related]
8. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927 [TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075 [TBL] [Abstract][Full Text] [Related]
10. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Duong VH; Baer MR; Hendrick F; Weiss SR; Sato M; Zeidan AM; Gore SD; Davidoff AJ Leuk Res; 2015 Jun; 39(6):586-91. PubMed ID: 25869077 [TBL] [Abstract][Full Text] [Related]
11. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Platzbecker U; Symeonidis A; Oliva EN; Goede JS; Delforge M; Mayer J; Slama B; Badre S; Gasal E; Mehta B; Franklin J Leukemia; 2017 Sep; 31(9):1944-1950. PubMed ID: 28626220 [TBL] [Abstract][Full Text] [Related]
12. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E; Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103 [TBL] [Abstract][Full Text] [Related]
13. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents. Silver MR; Geronemus R; Krause M; Chen CY; Kewalramani R; Stehman-Breen C Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145 [TBL] [Abstract][Full Text] [Related]
14. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data. Aslaner Ak M; Gedük A; Acar İH; Polat MG; Sunu C; Bolaman AZ; Hacıbekiroğlu T; Güvenç B; Ertop Ş Turk J Haematol; 2023 May; 40(2):92-100. PubMed ID: 36799095 [TBL] [Abstract][Full Text] [Related]
16. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341 [TBL] [Abstract][Full Text] [Related]
17. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial. Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263 [TBL] [Abstract][Full Text] [Related]
18. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615 [TBL] [Abstract][Full Text] [Related]
19. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Galle JC; Claes K; Kiss I; Winearls CG; Herlitz H; Guerin A; Di Giulio S; Suranyi MG; Bridges I; Addison J; Farouk M Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136 [TBL] [Abstract][Full Text] [Related]
20. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]